The EUTOS long-term survival (ELTS) score is superior to the
Sokal score for predicting survival in chronic myeloid leukemia

J 2020

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

PFIRRMANN, M., R. E. CLARK, W. PREJZNER, M. LAUSEKER, M. BACCARANI et. al.

Základní údaje

Originální název

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

Autoři

PFIRRMANN, M. (276 Německo, garant), R. E. CLARK (826 Velká Británie a Severní Irsko), W. PREJZNER (616 Polsko), M. LAUSEKER (276 Německo), M. BACCARANI (380 Itálie), S. SAUSSELE (276 Německo), F. GUILHOT (250 Francie), S. HEIBL (40 Rakousko), R. HEHLMANN (276 Německo), E. FABER (203 Česká republika), A. TURKINA (643 Rusko), G. OSSENKOPPELE (528 Nizozemské království), M. HOGLUND (752 Švédsko), A. ZARITSKEY (643 Rusko), L. GRISKEVICIUS (440 Litva), U. OLSSON-STROMBERG (752 Švédsko), H. EVERAUS (233 Estonsko), P. KOSKENVESA (246 Finsko), B. LABAR (191 Chorvatsko), T. SACHA (616 Polsko), Daniela ŽÁČKOVÁ (203 Česká republika, domácí), F. CERVANTES (724 Španělsko), A. COLITA (642 Rumunsko), I. ZUPAN (705 Slovinsko), A. BOGDANOVIC (688 Srbsko), F. CASTAGNETTI (380 Itálie), J. GUILHOT (250 Francie), J. HASFORD (276 Německo), A. HOCHHAUS (276 Německo) a V. S. HOFFMANN (276 Německo)

Vydání

Leukemia, London, Nature Publishing Group, 2020, 0887-6924

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 11.528

Kód RIV

RIV/00216224:14110/20:00116177

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1038/s41375-020-0931-9

UT WoS

000544139100003

Klíčová slova anglicky

PROGNOSTIC DISCRIMINATION; IMATINIB TREATMENT; CML; VALIDATION; BOSUTINIB; DASATINIB; FRONTLINE; MODELS

Štítky

14110212, rivok

Změněno: 29. 10. 2020 13:37, Mgr. Tereza Miškechová

Anotace

V originále

Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our aim was to compare the prognostic performance of the scores and to arrive at an evidence-based score recommendation. In 2949 patients not involved in any score development, higher hazard ratios and concordance indices in any comparison demonstrated the best discrimination of long-term survival with the ELTS score. In a second step, of 5154 patients analyzed to investigate risk group classification differences, 23% (n = 1197) were allocated to high-risk by the Sokal score. Of the 1197 Sokal high-risk patients, 56% were non-high-risk according to the ELTS score and had a significantly more favorable long-term survival prognosis than the 526 high-risk patients according to both scores. The Sokal score identified too many patients as high-risk and relatively few (40%) as low-risk (versus 60% with the ELTS score). Inappropriate risk classification jeopardizes optimal treatment selection. The ELTS score outperformed the Sokal score, the Euro, and the EUTOS score regarding risk group discrimination. The recent recommendation of the European LeukemiaNet for preferred use of the ELTS score was supported with significant statistical evidence.

Citovat

PFIRRMANN, M., R. E. CLARK, W. PREJZNER, M. LAUSEKER, M. BACCARANI, S. SAUSSELE, F. GUILHOT, S. HEIBL, R. HEHLMANN, E. FABER, A. TURKINA, G. OSSENKOPPELE, M. HOGLUND, A. ZARITSKEY, L. GRISKEVICIUS, U. OLSSON-STROMBERG, H. EVERAUS, P. KOSKENVESA, B. LABAR, T. SACHA, Daniela ŽÁČKOVÁ, F. CERVANTES, A. COLITA, I. ZUPAN, A. BOGDANOVIC, F. CASTAGNETTI, J. GUILHOT, J. HASFORD, A. HOCHHAUS a V. S. HOFFMANN. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. London: Nature Publishing Group, 2020, roč. 34, č. 8, s. 2138-2149. ISSN 0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-020-0931-9.

@article{1673771,
   author = {Pfirrmann, M. and Clark, R. E. and Prejzner, W. and Lauseker, M. and Baccarani, M. and Saussele, S. and Guilhot, F. and Heibl, S. and Hehlmann, R. and Faber, E. and Turkina, A. and Ossenkoppele, G. and Hoglund, M. and Zaritskey, A. and Griskevicius, L. and OlssonandStromberg, U. and Everaus, H. and Koskenvesa, P. and Labar, B. and Sacha, T. and Žáčková, Daniela and Cervantes, F. and Colita, A. and Zupan, I. and Bogdanovic, A. and Castagnetti, F. and Guilhot, J. and Hasford, J. and Hochhaus, A. and Hoffmann, V. S.},
   article_location = {London},
   article_number = {8},
   doi = {http://dx.doi.org/10.1038/s41375-020-0931-9},
   keywords = {PROGNOSTIC DISCRIMINATION; IMATINIB TREATMENT; CML; VALIDATION; BOSUTINIB; DASATINIB; FRONTLINE; MODELS},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia},
   url = {https://www.nature.com/articles/s41375-020-0931-9.pdf},
   volume = {34},
   year = {2020}
}

TY  - JOUR
ID  - 1673771
AU  - Pfirrmann, M. - Clark, R. E. - Prejzner, W. - Lauseker, M. - Baccarani, M. - Saussele, S. - Guilhot, F. - Heibl, S. - Hehlmann, R. - Faber, E. - Turkina, A. - Ossenkoppele, G. - Hoglund, M. - Zaritskey, A. - Griskevicius, L. - Olsson-Stromberg, U. - Everaus, H. - Koskenvesa, P. - Labar, B. - Sacha, T. - Žáčková, Daniela - Cervantes, F. - Colita, A. - Zupan, I. - Bogdanovic, A. - Castagnetti, F. - Guilhot, J. - Hasford, J. - Hochhaus, A. - Hoffmann, V. S.
PY  - 2020
TI  - The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
JF  - Leukemia
VL  - 34
IS  - 8
SP  - 2138-2149
EP  - 2138-2149
PB  - Nature Publishing Group
SN  - 08876924
KW  - PROGNOSTIC DISCRIMINATION
KW  - IMATINIB TREATMENT
KW  - CML
KW  - VALIDATION
KW  - BOSUTINIB
KW  - DASATINIB
KW  - FRONTLINE
KW  - MODELS
UR  - https://www.nature.com/articles/s41375-020-0931-9.pdf
L2  - https://www.nature.com/articles/s41375-020-0931-9.pdf
N2  - Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our aim was to compare the prognostic performance of the scores and to arrive at an evidence-based score recommendation. In 2949 patients not involved in any score development, higher hazard ratios and concordance indices in any comparison demonstrated the best discrimination of long-term survival with the ELTS score. In a second step, of 5154 patients analyzed to investigate risk group classification differences, 23% (n = 1197) were allocated to high-risk by the Sokal score. Of the 1197 Sokal high-risk patients, 56% were non-high-risk according to the ELTS score and had a significantly more favorable long-term survival prognosis than the 526 high-risk patients according to both scores. The Sokal score identified too many patients as high-risk and relatively few (40%) as low-risk (versus 60% with the ELTS score). Inappropriate risk classification jeopardizes optimal treatment selection. The ELTS score outperformed the Sokal score, the Euro, and the EUTOS score regarding risk group discrimination. The recent recommendation of the European LeukemiaNet for preferred use of the ELTS score was supported with significant statistical evidence.
ER  -

PFIRRMANN, M., R. E. CLARK, W. PREJZNER, M. LAUSEKER, M. BACCARANI, S. SAUSSELE, F. GUILHOT, S. HEIBL, R. HEHLMANN, E. FABER, A. TURKINA, G. OSSENKOPPELE, M. HOGLUND, A. ZARITSKEY, L. GRISKEVICIUS, U. OLSSON-STROMBERG, H. EVERAUS, P. KOSKENVESA, B. LABAR, T. SACHA, Daniela ŽÁČKOVÁ, F. CERVANTES, A. COLITA, I. ZUPAN, A. BOGDANOVIC, F. CASTAGNETTI, J. GUILHOT, J. HASFORD, A. HOCHHAUS a V. S. HOFFMANN. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. \textit{Leukemia}. London: Nature Publishing Group, 2020, roč.~34, č.~8, s.~2138-2149. ISSN~0887-6924. Dostupné z: https://dx.doi.org/10.1038/s41375-020-0931-9.

Podrobný výpis o publikaci